Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Is Takeda's Consumer Unit 'Agile' Enough To Stretch Outside Japan?

Executive Summary

Takeda says spinning off its consumer product portfolio into a wholly owned and independent subsidiary will boost its profile in the sector, but all signs continue to point to the firm's Rx operations as its predominant revenue drivers.

You may also be interested in...



Biopharma Quarterly Deal-Making Statistics, Q1 2017

Biopharma financing decreased by 29% in the first quarter of 2017; conversely, M&As set a record, reaching $61.9 billion. The largest alliance of the quarter involved the microbiome.

Takeda Acquires Ariad In $5.2bn Deal – US Infrastructure A Key Component?

Takeda will pay $5.2bn to buy Ariad Pharmaceuticals, the developer of one marketed cancer therapy, Iclusig – but the latter firm's US location and operations could be other important draws for the Japanese big pharma, which has previously announced plans to overhaul its own R&D activities.

Evolving Takeda Signals Intent To Build Around Entyvio, GI Franchise

Deals with TiGenix and Altos add to a growing gastrointestinal pipeline, as the Japanese pharma sees Entyvio and GI, not Velcade and cancer, as its primary growth-driver.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS120087

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel